Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer
Overview[ - collapse ][ - ]
| Purpose | Evaluate the efficacy of Abraxane in first line chemotherapy of patients with hormone refractory metastatic prostate cancer, based on prostate specific antigen (PSA) response |
|---|---|
| Condition | Prostate Cancer |
| Intervention | Drug: Abraxane |
| Phase | Phase 2 |
| Sponsor | Kaiser Permanente |
| Responsible Party | Kaiser Permanente |
| ClinicalTrials.gov Identifier | NCT00284752 |
| First Received | January 30, 2006 |
| Last Updated | September 28, 2012 |
| Last verified | September 2012 |
Tracking Information[ + expand ][ + ]
| First Received Date | January 30, 2006 |
|---|---|
| Last Updated Date | September 28, 2012 |
| Start Date | August 2005 |
| Estimated Primary Completion Date | December 2011 |
| Current Primary Outcome Measures |
|
| Current Secondary Outcome Measures |
|
Descriptive Information[ + expand ][ + ]
| Brief Title | Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer |
|---|---|
| Official Title | Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer |
| Brief Summary | Evaluate the efficacy of Abraxane in first line chemotherapy of patients with hormone refractory metastatic prostate cancer, based on prostate specific antigen (PSA) response |
| Detailed Description | Taxanes are the most widely tested and effective chemotherapy drugs for hormone refractory prostate cancer. Weekly paclitaxel was reported to produce 25-39% PSA responses in first line and up to 33% in second line chemotherapy of patients with prostate cancer in early clinical trials (1, 2). Paclitaxel activity in prostate cancer is schedule dependent, and weekly paclitaxel was reported to produce highest response rates (1, 2). Docetaxel was recently approved by the Food and Drug Administration for treatment of hormone refractory metastatic prostate cancer, since it is the only chemotherapy drug with documented improvement in survival in this group of patients. Docetaxel was associated with 45.8% overall grade 3/4 toxicities and it has to be given with steroid pre-medication. This regimen might be difficult to use in advanced prostate cancer patients that are often elderly and with multiple co-morbid conditions. ABI-007 [Abraxane™ (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)] is the first in its class of biologically interactive albumin-bound forms of chemotherapy (3). This composition provides a novel approach of increasing intra-tumoral concentration of the drug by a receptor-mediated transport process allowing transcytosis across the endothelial cell wall, thereby breaching the blood/tumor interface. This albumin-specific receptor mediated process involves the binding of a specific receptor (gp60) on the endothelial cell wall, resulting in activation of a protein caveolin-1, which initiates an opening in the endothelial wall with formation of a little caves or caveolae, with transport of the albumin-bound chemotherapeutic complex via these caveolae to the underlying tumor interstitium (4). A protein specifically secreted by the tumor (SPARC) binds and entraps the albumin, allowing release of the hydrophobic drug to the tumor cell membrane. ABI-007 is the first biologically interactive albumin-bound chemotherapy agent leveraging this gp-60/caveolin-1/caveolae/Sparc pathway to increase intra-tumoral concentration of the drug and reduce the amount of the toxic chemotherapy in normal tissue. Preclinical studies comparing Abraxane to paclitaxel demonstrated lower toxicities, with a maximum tolerated dose (MTD) approximately 50% higher for Abraxane (7) compared to paclitaxel (11). At equal doses there was less myelosuppression and improved efficacy than paclitaxel in a xenograft tumor model of human mammary adenocarcinoma. Clinical studies confirmed improved toxicity profile and higher response rates, in metastatic breast cancer, of Abraxane compared to cremophor EL paclitaxel (Taxol) (5, 8). The weekly regimen was shown to be active even in patients with cancers refractory to paclitaxel, docetaxel or when Abraxane was given after both agents (8). |
| Study Type | Interventional |
| Study Phase | Phase 2 |
| Study Design | Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment |
| Condition | Prostate Cancer |
| Intervention | Drug: Abraxane This is a Phase II single-arm study for first-line chemotherapy of patients with hormone refractory metastatic prostate cancer. Eligible patients will be chemotherapy naive and will receive weekly Abraxane 100mg/m2 IV over 30 minutes. These will be 4-week cycles with patients receiving Abraxane 100 mg/m2 weekly for 3 weeks and one week off for rest. Patients will continue on therapy until disease or PSA |
| Study Arm (s) | Experimental: ABI-007 |
Recruitment Information[ + expand ][ + ]
| Recruitment Status | Completed |
|---|---|
| Estimated Enrollment | 56 |
| Estimated Completion Date | December 2011 |
| Estimated Primary Completion Date | October 2007 |
| Eligibility Criteria | Inclusion Criteria: 1. Histopathologically or cytologically proven adenocarcinoma of the prostate metastatic to the bones or lymph nodes as documented by bone scan or CT scan with evidence of progression despite standard hormonal management (orchiectomy, GNRH agonist, or GNRH antagonist-hormone refractory). No major organ allowed 2. No prior chemotherapy 3. For patients who have been on anti-androgen therapy, patients must have progressive disease after anti-androgen withdrawal (6 weeks biclutamide or nilutamide, 4 weeks for flutamide). 4. PSA progression is defined as rising PSA. Exclusion Criteria: 1. Active malignancy other than non-melanoma skin cancer within 5 years of enrollment. 2. Significant active medical illness which in the opinion of the investigator will preclude treatment. 3. Brain metastasis, any non-bone metastasis except lymph node metastasis |
| Gender | Male |
| Ages | 18 Years |
| Accepts Healthy Volunteers | No |
| Contacts | Not Provided |
| Location Countries | United States |
Administrative Information[ + expand ][ + ]
| NCT Number | NCT00284752 |
|---|---|
| Other Study ID Numbers | TK001 |
| Has Data Monitoring Committee | Not Provided |
| Information Provided By | Kaiser Permanente |
| Study Sponsor | Kaiser Permanente |
| Collaborators | Celgene Corporation |
| Investigators | Principal Investigator: Tatjana Kolevska, MD Kaiser Permanente |
| Verification Date | September 2012 |
Locations[ + expand ][ + ]
| Kaiser Permanente | Vallejo, California, United States, 94589 |
|---|